Abstract Number: PB1354
Meeting: ISTH 2020 Congress
Background: Heparin induced thrombocytopenia (HIT) is a life threatening complicationand requires highly priortize managment It is suggested by decrease in the number of platelet count during or shortly after heparin therapy by any route in the absence of other medical conditions responsible for thrombocytopenia.
Aims: To evaluate the significance of platelet factor 4 (PF4 antibody) in diabetic and non-diabetic population during heparin therapy at LUMHS Jamshoro Pakistan.
Methods: The cross sectional comparative study of one year was conducted at LUMHS Jamshoro. All the (diabetic and non diabetic Patients) already on heparin therapy for 1-7 days duration, due to any clinical disorder, of 18-70 years of age. The patients were observed for changes in the number of platelet count the day after the heparin therapy by advising (CBC) performed Sysmex XN1000 I japan. HBA1C were performed ARKRAY ADAMS A1C lite HA 8380V. Platelet Factor 4 antibodies were detected on ID PaGIA Heparin/PF4 antibody test. The data was analyzed in SPSS, the frequency and percentage was calculated for catagorical variables mean ± SD was calculated for numerical variables.
Results: Total 173 individuals were included in this study which consists of diabetic and non-diabetic population,The diabetic and non diabetic population documented as 80 (46.2%) and 93 (53.8%). The majority of the patients (71.6%) were in 30-59 year age group followed by age group 40-59 years ). The male and female population were reported as 100(57.8%)and73 (42.2%). The PF4 antibodies were identified in 63 (36.4%) individuals. The PF4 antibodies in context to age of the population was statistically significant (p-value 0.00) while the PF4 antibodies in context to thrombocytopenia was statistically significant (p-value 0.00). The PF4 antibodies in context to gender of the population were statistically significant (p-value 0.00).
Conclusions: Diabetes mellitus is associated with a higher likelihood of developing heparin induced antibodies and an increased combined incidence of arterial complications.
To cite this abstract in AMA style:Abbasi RA, Ujjan ID, Naz A, Amir K, Hafeez N. The Significance of Platelet Factor 4 (Pf4 Antibody) in Diabetic and Non-Diabetic Population during Heparin Therapy In Pakistan [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/the-significance-of-platelet-factor-4-pf4-antibody-in-diabetic-and-non-diabetic-population-during-heparin-therapy-in-pakistan/. Accessed September 24, 2023.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/the-significance-of-platelet-factor-4-pf4-antibody-in-diabetic-and-non-diabetic-population-during-heparin-therapy-in-pakistan/